Trials / Withdrawn
WithdrawnNCT05826015
AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Phase I/IB of AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine safety and tolerability of AVB-500 when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel | IV over 3 hours |
| DRUG | Batiraxcept | IV over 60 minutes |
Timeline
- Start date
- 2024-10-31
- Primary completion
- 2029-06-03
- Completion
- 2034-06-04
- First posted
- 2023-04-24
- Last updated
- 2024-10-02
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05826015. Inclusion in this directory is not an endorsement.